Research on the cell biology of tumors. Covers cancer-cell vulnerabilities, tumor spread, nanoreactor therapies, and AI-guided cancer research.
Researchers successfully tagged telomerase with fluorescent molecules, revealing its two-step binding mode to chromosomes. The study also shows how telomerase mutation promotes tumorigenesis, offering a new target for therapeutic strategies.
Researchers found that terahertz radiation can disrupt protein filaments in both aqueous solutions and living cells, but does not kill the cells. This discovery has implications for potential applications in cancer treatment, as well as safety concerns.
Researchers found that cancer cells activate an inflammatory response when in contact with fibroblasts, making it harder for viruses to infect them. By blocking this signaling pathway, oncolytic viruses can more effectively target cancer cells, offering a potential treatment option.
Researchers at Hokkaido University have developed an adenovirus that specifically replicates in and kills cancer cells using RNA-stabilizing elements. The virus, AdARET, was found to be effective against a range of cancer types, including those without a mutated RAS gene.
Researchers found that cancer therapy can trigger the formation of large, aggressive cells with multiple chromosomes. A scientist is now developing a drug to prevent or treat these rogue cells, which can lead to cancer recurrence.
Researchers at CSIC pioneer the use of whole living cells in dynamic combinatorial chemistry systems to discover new bioactive molecules. This methodology has great potential in rapidly identifying new molecules with potential biological activity, and could lead to faster discovery of bioactive compounds.
Researchers have confirmed biological hallmarks of survival in tumor cells and identified two processes linked to high-grade serous carcinoma. Proteomics analysis reveals details about protein communication and function in cancerous cells, providing insights into the 'broken' machinery behind ovarian cancer.
A newly identified biomarker could help scientists pinpoint which cancers are vulnerable to treatment with biguanides, a common class of medications used to control blood sugar in Type 2 diabetes. The biomarker is linked to the gene MYC and has been found to be regulated by microRNAs that target certain cancer cells.
A new imaging method detects metabolic and structural changes in cervical epithelial cells using intrinsic fluorescence, enabling early-stage bedside diagnosis. This non-invasive approach opens up a routine monitoring strategy for patients at high risk of cervical cancer.
Researchers created a way to study and map intercellular signaling to understand cell movement mechanisms in healthy cells and disease states like cancer metastasis. The new tool uses microscopy tools and mathematical methods to visualize protein activity and quantify regulation of signaling networks.
A new study from Scripps Research reveals that the protein YAP plays a dual role in regulating cell growth, both promoting and inhibiting proliferation. This finding has significant implications for understanding cancer behavior and developing targeted therapies.
Researchers at IST Austria found that actin flows from front to tail, driving cell movement, and can couple with environment without integrins, enabling flexible crawling through tissues. This 'off-road' mode of locomotion allows cells to migrate efficiently in various environments.
Researchers at Université catholique de Louvain discovered that cancer cells can deactivate the CD166 'Velcro' protein on their surface, allowing them to migrate more easily and form metastases. This fundamental mechanism may lead to the development of new solutions to block metastasis and slow down cancer progression.
A research team at Pohang University of Science & Technology has developed an integrative cancer therapy using adoptive natural killer cell therapy and chemotherapy. The new method enhances the effectiveness of cell therapy in treating solid cancers by selectively releasing anticancer drugs, reducing side effects.
A new study has identified a crucial role for the protein RTEL1 in the survival of cancer cells, with potential implications for treating various types of cancer. Researchers found that RTEL1 prevents damaging clashes between DNA replication and transcription processes, and promotes a process called MiDAS, which is common in cancer cells.
Scientists at the University of Oxford have discovered a new way for T cells to attack cells infected by viruses or cancer. Supramolecular attack particles (SMAPs), released from cytotoxic T lymphocytes, can autonomously kill targeted cells, providing a complementary mechanism of cytotoxicity.
Researchers are teaming up to understand why critical nerve cells continue to die after spinal cord injuries and aim to develop more effective treatments by enhancing or limiting the immune response. They'll use a new probe developed by one scientist to track dead cells as they're swallowed up by immune cells.
Researchers from Skoltech have made significant progress in understanding the apoptotic program, a crucial process for removing unneeded or abnormal cells. The study has identified key proteins involved in this process, which could lead to new therapeutic targets for treating cancer.
Researchers at TUM have discovered a novel mechanism that inhibits cancer-specific immune responses, leading to the development of new immunotherapies. The discovery identifies a suppressive metabolite from glucose metabolism as a key factor in limiting cancer immunity.
Hyperdiploid B-ALL, the most common subtype of pediatric leukemia, arises from a malfunctioning Condensin complex, Aurora B kinase, and mitotic checkpoint in cell division. Researchers have unveiled the molecular mechanisms underlying HyperD-ALL origin and progression.
Scientists have developed a multi-functional graphene-based nanomedicine that targets cancer cells with enhanced anticancer activity. The material, which combines three types of molecules for improved tumor targeting and drug delivery, shows promise for future biomedical applications.
Bayreuth geneticists have discovered a natural protective mechanism that leads to the programmed death of potentially diseased cells. The separase enzyme plays a central role in this process and can be re-purposed to induce apoptosis in cancer cells.
The study found that combinations of paclitaxel (PAC) and withaferin A (WFA) are highly synergistic against human non-small cell lung cancer cells, showing greater sensitivity than either treatment alone. WFA was active against PAC-sensitive and PAC-resistant NSCLC cells, demonstrating its potential therapeutic efficacy.
Researchers found that pancreatic cancer cells use autophagy to degrade MHC-I proteins, making them resistant to immunotherapies. Blocking autophagy or using drugs like chloroquine enhances MHC-I expression on the surface of cancer cells, increasing their susceptibility to immunotherapy.
A study has identified frequent cancer-driving mutations in healthy human endometrium, suggesting that these events may occur early in life. These mutant stem cells can accumulate further driver mutations over time, leading to invasive cancer years or even decades later.
Researchers at Salk Institute discover formation of tuft cells during pancreatitis, which secrete IL-25 to promote immune response. The finding may lead to development of new treatments for pancreatitis and pancreatic cancer.
Researchers at Skoltech and MIT have developed a new combinatorial therapy for liver cancer using a siRNA approach coupled with lipid nanoparticle technology. This treatment caused a significant decrease in tumor load in a mouse model of hepatocellular carcinoma.
Researchers at Penn State have directly observed functional metabolons involved in generating purines, the most abundant cellular metabolites. The findings suggest that enzymes are not haphazardly located throughout cells but instead occur in discrete clusters, or metabolons, that carry out specific metabolic pathways.
A new study led by UT Southwestern scientists suggests that tumors can manipulate the cell death signaling pathway to evade an immune response after radiation. By blocking this pathway, researchers found that cancer cells can secrete more interferons, which triggers a tumor-fighting immune response.
The VRAC ion channel transports the messenger substance cGAMP from cell to cell, strengthening the immune response to DNA virus infections. This discovery could also have implications for cancer treatment and new strategies against DNA viruses.
Researchers at the University of Freiburg have discovered that cancer-causing mutations in the KRAS gene lead to inflammation and slow down tumor growth. The study, led by Prof. Dr. Robert Zeiser, shows that K-Ras plays a dual role in both cancer development and immune response.
A team of NYU Abu Dhabi researchers have developed a new, one-pot synthetic approach to obtain water-stable and ready-to-use gold nanoparticles. These nanoparticles can be heated with a simple green laser, improving their ability to penetrate and destroy malignant cells through hyperthermia while releasing chemotherapeutic drugs.
A team of researchers from RIKEN has developed a new single-cell RNA sequencing method called Quartz-seq2 that outperforms other methods in terms of accuracy and reproducibility. The method was benchmarked against 13 different methods using a set of approximately 3,000 cells, and it scored highest on the benchmark.
Researchers at the Medical University of South Carolina have discovered a natural product, manzamine A, that exhibits anti-cancer properties in cervical cancer cells. The compound stops cell growth and causes some cells to die, with potential applications for treatment and development.
A new study found that mother cells decide whether their daughter cells will divide based on environmental growth factors. The discovery could lead to longer windows for cancer drug therapies.
Scientists have engineered T-cells to target multiple sites on leukemia cells, offering a more effective treatment for resistant acute lymphoblastic leukemia. The new CAR-T therapy, TriCAR T-cells, targeting CD-19/20/22, demonstrate improved efficacy compared to single-antigen therapies.
A virtual computational cell was built to predict cancer metastasis by analyzing the interaction of numerous molecules and signals within the tumor environment. The research found that hybrid cancer cells can be targeted using specific molecular signals and extracellular matrix proteins, offering new therapeutic strategies against cancer.
Researchers at MD Anderson Cancer Center propose using glucose transporter inhibitors to treat tumors with high expression of the SLC7A11 amino acid transporter. This approach targets cancer cells' dependency on glucose for survival, selectively killing 'addicted' cells.
Researchers have discovered that cancer cells use fats as an energy source when detached from their point of origin, and that limiting access to a specific enzyme may starve them of this resource. The study suggests that an existing drug could be repurposed to treat chemo-resistant ovarian cancer.
Researchers used microelectrode arrays implanted in brains of two individuals with chronic tetraplegia to map motor functions down to single nerve cells. The study found that an area previously thought to control only one body part actually operates across a wide range of motor functions, demonstrating coordination between neurons.
Researchers at UC Davis have discovered that changes in surface sugarlike molecules, or glycans, on cancer cells help them metastasize. The study found that cancer cells with high levels of mannose glycan were more likely to spread into surrounding tissues.
Researchers at University of Sydney have found a new way cancer cells can escape and become more aggressive, resisting chemotherapy. This discovery opens up new possibilities for developing targeted treatments against this previously unknown pathway.
A new mass cytometry technique has identified key proteins in blood cancer cells, revealing why some cells are resistant to standard anti-cancer drugs. The research team hopes to apply this protocol to clinical trials to better understand why some cancers are resistant to therapies and match patients with more effective treatments.
Researchers found that increased lysosome numbers lead to hyperactivation of mTOR, stimulating abnormal cell growth. The study identified Rap1 as a regulator of lysosomal network organization and lysosome number, highlighting the central role of lysosomes in cancer progression.
Cancer cells rely on different factors for survival when DNA replication is blocked. Researchers found that inhibiting a key protein called Cdc7 selectively kills cancer cells by inactivating their safety mechanism. This discovery provides a new strategy for targeting cancer cells and developing anti-cancer agents.
Research reveals a new mechanism for controlling DNA methylation in cells, involving the ubiquitination of PAF15, which is crucial for maintaining DNA methylation and inhibiting cancer cell proliferation. The discovery has significant implications for the development of new inhibitors of DNA methyltransferase
Researchers have engineered silkworms to produce different variants of E-selectin, a critical adhesion molecule involved in inflammation, cancer, and disease processes. The study found that the connecting arm of E-selectin is crucial for binding, while longer armed proteins are better at tethering blood stem cells.
Cancer cells can form large-scale structures in the laboratory, similar to those seen in vivo, allowing researchers to gain insight into the forces behind this phenomenon. The study suggests that understanding these interactions may hold potential for combating cancer.
Researchers found a method to promote cancer cell growth using silica-coated gold nanorods exposed to near infrared light, with a 36.13% higher growth rate than normal incubator conditions. The heat shock proteins induced by the nano heat islands helped protein folding and cell survival.
Researchers developed a substance that targets cancer cells with defective NAT2 gene, potentially treating colorectal cancer patients worldwide
Researchers developed a microfluidics device that isolates cancer cells from urine, achieving high detection rates of up to 85% and 86% for localized cancer cases. The new method provides an alternative to invasive tissue biopsies and blood tests with false positive results.
Researchers have synthesized manganese-zinc ferrite nanoparticles that can deactive cancer cells without harming healthy tissues. The particles' unique magnetic properties allow them to heat up only at the Curie temperature, making them suitable for treating cancer with minimal damage.
The μMap technology uses a photocatalyst to identify spatial relationships on cell surfaces, enabling precise mapping of protein micro-environments. This breakthrough could impact proteomics, genomics, and neuroscience, with potential applications in fundamental biology.
Researchers have successfully tested molecular motors that can destroy diseased cells in worms, plankton, and mice. The nanomachines caused various degrees of damage to tissues, showing their potential for treating skin diseases such as melanomas and eczema.
New research identifies NMT1 and NMT2 enzymes as regulators of the ARF6 GTPase cycle, allowing scientists to control cell signaling and potentially treat diseases such as cancer and viral infections.
Cancer cells exploit a protein to break through tissue boundaries, increasing motility and invasiveness.
Researchers at Northwestern University have developed a promising molecular tool that targets and inhibits telomerase, an enzyme that enables cancer cells to live forever. The small molecule, called NU-1, irreversibly binds to telomerase, shutting down its activity and sensitizing cells to chemotherapies.
Researchers identified subpopulations of leukemia cells present at diagnosis that have distinct characteristics, leading to relapse in children and adults. These findings provide new avenues for overcoming resistance and improving treatment approaches.
The study found that SLC25A32 inhibition resulted in anti-proliferative effects on certain tumor cell lines, potentially by increasing reactive oxygen species. Treatment with riboflavin and glutathione rescued cancer cell proliferation upon SLC25A32 down-regulation.
Researchers have discovered that cancer cells can tolerate high amounts of single-stranded DNA, which is a common sign of stress during cell division. By inhibiting the POLA1 gene, cells can be made to crash when they divide, potentially leading to new cancer treatments.